These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12691125)

  • 1. Value of whole-body FDG PET in management of lung cancer.
    Higashi K; Matsunari I; Ueda Y; Ikeda R; Guo J; Oguchi M; Tonami H; Yamamoto I
    Ann Nucl Med; 2003 Feb; 17(1):1-14. PubMed ID: 12691125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET in lung cancer.
    Coleman RE
    J Nucl Med; 1999 May; 40(5):814-20. PubMed ID: 10319756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of PET in lung cancer.
    Al-Sugair A; Coleman RE
    Semin Nucl Med; 1998 Oct; 28(4):303-19. PubMed ID: 9800237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology.
    Kubota K
    Ann Nucl Med; 2001 Dec; 15(6):471-86. PubMed ID: 11831394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
    Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
    J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
    Buck AK; Halter G; Schirrmeister H; Kotzerke J; Wurziger I; Glatting G; Mattfeldt T; Neumaier B; Reske SN; Hetzel M
    J Nucl Med; 2003 Sep; 44(9):1426-31. PubMed ID: 12960187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer.
    Kamel EM; Zwahlen D; Wyss MT; Stumpe KD; von Schulthess GK; Steinert HC
    J Nucl Med; 2003 Dec; 44(12):1911-7. PubMed ID: 14660716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax.
    Demura Y; Tsuchida T; Ishizaki T; Mizuno S; Totani Y; Ameshima S; Miyamori I; Sasaki M; Yonekura Y
    J Nucl Med; 2003 Apr; 44(4):540-8. PubMed ID: 12679397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT.
    Christensen JA; Nathan MA; Mullan BP; Hartman TE; Swensen SJ; Lowe VJ
    AJR Am J Roentgenol; 2006 Nov; 187(5):1361-7. PubMed ID: 17056930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management.
    Dewan NA; Gupta NC; Redepenning LS; Phalen JJ; Frick MP
    Chest; 1993 Oct; 104(4):997-1002. PubMed ID: 8404239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of 18F-FDG PET in evaluating cancers of lung.
    Acker MR; Burrell SC
    J Nucl Med Technol; 2005 Jun; 33(2):69-74; quiz 75-7. PubMed ID: 15930019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of
    Delgado Bolton RC; Calapaquí-Terán AK; Giammarile F; Rubello D
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(4):229-233. PubMed ID: 31202725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules.
    Bryant AS; Cerfolio RJ
    Ann Thorac Surg; 2006 Sep; 82(3):1016-20. PubMed ID: 16928527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoro-deoxy-glucose positron emission tomography for evaluation of indeterminate lung nodules: assigning a probability of malignancy may be preferable to binary readings.
    Kim SC; Machac J; Krynyckyi BR; Knesaurek K; Krellenstein D; Schultz B; Gribetz A; DePalo L; Teirstein A; Kim CK
    Ann Nucl Med; 2008 Apr; 22(3):165-70. PubMed ID: 18498030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
    Aquino SL; Fischman AJ
    Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.
    Hsieh HJ; Lin SH; Lin KH; Lee CY; Chang CP; Wang SJ
    Ann Nucl Med; 2008 Jul; 22(6):533-8. PubMed ID: 18670862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma.
    Sasaki M; Kuwabara Y; Koga H; Nakagawa M; Chen T; Kaneko K; Hayashi K; Nakamura K; Masuda K
    Ann Nucl Med; 2002 Jul; 16(5):337-45. PubMed ID: 12230093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.